Reviewing Kymera Therapeutics (KYMR) and Its Competitors

Kymera Therapeutics (NASDAQ:KYMR) is one of 848 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Kymera Therapeutics to related businesses based on the strength of its dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Kymera Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Kymera Therapeutics Competitors	-9,008.55%	-198.83%	-30.88%

Insider and Institutional Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Kymera Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	2	23	1	2.89
Kymera Therapeutics Competitors	9765	15037	45353	1577	2.54

Kymera Therapeutics presently has a consensus price target of $135.12, indicating a potential upside of 14.86%. As a group, “Biotechnology” companies have a potential upside of 93.92%. Given Kymera Therapeutics’ rivals higher probable upside, analysts plainly believe Kymera Therapeutics has less favorable growth aspects than its rivals.

Risk and Volatility

Kymera Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Kymera Therapeutics’ rivals have a beta of 1.12, indicating that their average share price is 12% more volatile than the S&P 500.

Valuation and Earnings

This table compares Kymera Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	-$311.35 million	-36.31
Kymera Therapeutics Competitors	$714.80 million	$12.22 million	-9.93

Kymera Therapeutics’ rivals have higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Kymera Therapeutics beats its rivals on 8 of the 13 factors compared.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.